Australian anti-cancer drug picked as one of the world’s top 10 most promising new drug products in 2011

18-Oct-2011 - Australia

Immune System Therapeutics (IST) announced its lead anti-cancer product, MDX-1097, had been recognized as one of Windhover's Top 10 most promising new drug products for 2011. Windhover is a provider of business information to the pharmaceutical, biotechnology, and medical device industries. MDX-1097 is IST’s lead anti-cancer candidate for the treatment of deadly multiple myeloma blood cancer. IST’s drug MDX-1097 was chosen using a variety of criteria, including mechanism of action, initial marketable indication , potential for follow-on indications and its potential for licensing.

"We are excited with the promise MDX-1097 has demonstrated to date in patients with multiple myeloma, and pleased that industry experts have recognized the potential of this new drug candidate to attract partners to accelerate its development," said IST Chief Executive Officer Dr Calum McKinlay.

In June 2011, MDX-1097 received orphan drug designation from US health regulators, giving the company and its potential licensing partners help with the regulatory approval process and marketing exclusivity in the US for a number of years.  IST also recently announced the expansion of its Phase IIa clinical trial in Australia following encouraging responses from the first dosed patients and positive safety data.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances

Last viewed contents

Novartis to expand its human vaccines presence in China through proposed acquisition of a majority stake in Zhejiang Tianyuan

Cytheris announces results of phase IIa study indicating that recombinant interleukin-7 (CYT107) expands CD4 T-Cells in gut mucosa of chronically HIV infected immunological non-responder patients

Chemokine Therapeutics Announces Preliminary Results of CTCE-9908 Phase IB/II Clinical Trial in Late Stage Cancer Patients

Cytheris announces results of phase II study indicating that recombinant Interleukin-7 (CYT107) expands CD4 T-cells in gut mucosa of chronically HIV infected immunological non-responder patients

Horizon Discovery Announces Collaboration with the National Cancer Institute and the National Human Genome Research Institute - Horizon’s rAAV gene targeting to be applied in cancer research programs, enabling the NCI and NHGRI to engineer human isogenic disease models

Antisoma receives FDA approval for oral fludarabine, plans commercialisation deal to bring drug to US patients

Asterix's Roman foes -- Researchers have a better idea of how cancer cells move and grow - In a number of biological processes, including in the formation of metastases, cells communicate with each other in order to move as a group

Asterix's Roman foes -- Researchers have a better idea of how cancer cells move and grow - In a number of biological processes, including in the formation of metastases, cells communicate with each other in order to move as a group

S*BIO Initiates Phase 2 Clinical Trial of its Novel JAK2 Inhibitor SB1518 in North America for Advanced Lymphoid Malignancies

Addex Initiates Phase IIa Clinical Trial of Dipraglurant-IR in Parkinson's Disease Levodopa-Induced Dyskinesia (PD-LID) - Second Phase IIa trial to begin this quarter with Addex allosteric modulators